Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUE90I)

Drug Name

AZD1656 Drug Info

Synonyms

AZD1656; AZD-1656; FJEJHJINOKKDCW-INIZCTEOSA-N; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide; SCHEMBL321593; GTPL7701; UNII-660M185X4D; CHEMBL3219124; AZD 1656; 660M185X4D; 89961-EP2305674A1; 89961-EP2301929A1; 89961-EP2301935A1; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methylpyrazin-2-yl)benzamide

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 2	[1]

Cross-matching ID

PubChem CID: 16039797
CAS Number: CAS 919783-22-5
TTD Drug ID: DMUE90I

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucokinase (GCK)	TTDLNGZ	HXK4_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Glucokinase (GCK)	DTT	GCK	2.722	4.76	1.848	3.945

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diabetic complication

ICD Disease Classification

5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucokinase (GCK)	DTT	GCK	2.72E-01	0.76	0.52

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7701).
2	Clinical pipeline report, company report or official report of AstraZeneca (2009).